Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525.

abstract：BACKGROUND:Antiangiogenic therapy of vestibular schwannoma (VS) in type 2 neurofibromatosis can produce tumor shrinkage with response rates of 40%-60%. This study examines the predictive value of parameter-derived MRI in this setting. METHODS:Twelve patients with 20 VSs were recruited. Each had at least one rapidly gr...

journal_title：Neuro-oncology

authors： Li KL,Djoukhadar I,Zhu X,Zhao S,Lloyd S,McCabe M,McBain C,Evans DG,Jackson A

更新日期：2016-02-01 00:00:00

abstract：:Transforming growth factor-beta (TGF-beta) is a proinvasive and immunosuppressive cytokine that plays a major role in the malignant phenotype of gliomas. One novel strategy of disabling TGF-beta activity in gliomas is to disrupt the signaling cascade at the level of the TGF-beta receptor I (TGF-betaRI) kinase, thus ab...

journal_title：Neuro-oncology

authors： Tran TT,Uhl M,Ma JY,Janssen L,Sriram V,Aulwurm S,Kerr I,Lam A,Webb HK,Kapoun AM,Kizer DE,McEnroe G,Hart B,Axon J,Murphy A,Chakravarty S,Dugar S,Protter AA,Higgins LS,Wick W,Weller M,Wong DH

更新日期：2007-07-01 00:00:00

abstract：:Secreted protein acidic and rich in cysteine (SPARC) has a suppressive effect on U87 glioma cell proliferation when assessed in vitro and in vivo using parental U87T2 and U87T2-derived SPARC-transfected clones. Since SPARCinteracts with extracellular matrix (ECM) proteins, we examined the effect of SPARC secretion on ...

journal_title：Neuro-oncology

authors： Vadlamuri SV,Media J,Sankey SS,Nakeff A,Divine G,Rempel SA

更新日期：2003-10-01 00:00:00

abstract：:Intradural spinal tumors are rare tumors of the central nervous system. Due to the eloquence of the spinal cord and its tracts, the compact architecture of the cord and nerves, and the infiltrative nature of some of these tumors, surgical resection is difficult to achieve without causing neurological deficits. Likewis...

journal_title：Neuro-oncology

authors： Abd-El-Barr MM,Huang KT,Moses ZB,Iorgulescu JB,Chi JH

更新日期：2018-05-18 00:00:00

abstract：:Current treatments for brain cancer have, for the most part, equivocal survival benefit. However, clinical trials of new anticancer agents do not adequately assess potential clinical benefits for patient function other than survival and time to tumor progression. We evaluated 56 patients with recurrent brain tumors wh...

journal_title：Neuro-oncology

authors： Meyers CA,Hess KR

更新日期：2003-04-01 00:00:00

abstract：:Although external beam radiation is an essential component to the current standard treatment of primary brain tumors, its application is limited by toxicity at doses more than 80 Gy. Recent studies have suggested that brachytherapy with liposomally encapsulated radionuclides may be of benefit, and we have reported met...

journal_title：Neuro-oncology

authors： Phillips WT,Goins B,Bao A,Vargas D,Guttierez JE,Trevino A,Miller JR,Henry J,Zuniga R,Vecil G,Brenner AJ

更新日期：2012-04-01 00:00:00

abstract：:The purpose of this study was to evaluate the activity of single-agent bevacizumab in patients with recurrent anaplastic glioma and assess correlative advanced imaging parameters. Patients with recurrent anaplastic glioma were treated with bevacizumab 10 mg/kg every 2 weeks. Complete patient evaluations were repeated ...

journal_title：Neuro-oncology

authors： Kreisl TN,Zhang W,Odia Y,Shih JH,Butman JA,Hammoud D,Iwamoto FM,Sul J,Fine HA

更新日期：2011-10-01 00:00:00

abstract：:The majority of meningiomas are probably benign but a number of tumors display considerable histological and/or clinical aggressivity, sometimes with unexpectedly high recurrence rates after radical removal. Understanding the potential behavior of these tumors in individual patients is critical for rational therapeuti...

journal_title：Neuro-oncology

authors： Pérez-Magán E,Rodríguez de Lope A,Ribalta T,Ruano Y,Campos-Martín Y,Pérez-Bautista G,García JF,García-Claver A,Fiaño C,Hernández-Moneo JL,Mollejo M,Meléndez B

更新日期：2010-12-01 00:00:00

abstract：BACKGROUND:Meningiomas are the most commonly diagnosed primary intracranial neoplasms. Despite significant advances in modern therapies, the management of malignant meningioma and skull base meningioma remains a challenge. Thus, the development of new treatment modalities is urgently needed for these difficult-to-treat...

journal_title：Neuro-oncology

authors： Iwami K,Natsume A,Ohno M,Ikeda H,Mineno J,Nukaya I,Okamoto S,Fujiwara H,Yasukawa M,Shiku H,Wakabayashi T

更新日期：2013-06-01 00:00:00

abstract：:A 67-year-old man presented with a 7-month history of insidiously progressive chorea, ataxia, and vertigo. Neurologic examination revealed deficits referable to the basal nuclei, cerebellar vermis, and vestibular nuclei. Small-cell lung cancer was diagnosed by fine-needle biopsy of a parahilar mass. After chemotherapy...

journal_title：Neuro-oncology

authors： Tremont-Lukats IW,Fuller GN,Ribalta T,Giglio P,Groves MD

更新日期：2002-07-01 00:00:00

abstract：:Karenitecin is a highly lipophilic camptothecin analogue with a lactone ring that is relatively resistant to inactivating hydrolysis under physiologic conditions. This phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) of karenitecin in adults with recurrent malignant glioma (MG), to de...

journal_title：Neuro-oncology

authors： Grossman SA,Carson KA,Phuphanich S,Batchelor T,Peereboom D,Nabors LB,Lesser G,Hausheer F,Supko JG,New Approaches to Brain Tumor Therapy CNS Consortium.

更新日期：2008-08-01 00:00:00

abstract：BACKGROUND:Recent molecular characterization studies have identified clinically relevant molecular subtypes to coexist within the same histological entities of glioma. Comparative studies between serum-supplemented and serum-free (SF) culture conditions have demonstrated that SF conditions select for glioma stem-like c...

journal_title：Neuro-oncology

authors： Balvers RK,Kleijn A,Kloezeman JJ,French PJ,Kremer A,van den Bent MJ,Dirven CM,Leenstra S,Lamfers ML

更新日期：2013-12-01 00:00:00

abstract：:A phase I trial of an engineered poliovirus for the treatment of recurrent glioblastoma (GBM) has attracted attention due to 8 survivors reaching the 24-month and 5 reaching the 36-month survival landmarks.1 Genetically engineered viruses (oncolytic viruses) have been in trials for GBM for almost two decades.2 These r...

journal_title：Neuro-oncology

authors： Chiocca EA,Nassiri F,Wang J,Peruzzi P,Zadeh G

更新日期：2019-01-01 00:00:00

abstract：:The Pediatric Oncology Group conducted a phase II study to evaluate the activity of carboplatin in children 5 years or younger with progressive optic pathway tumors (OPTs). Of the 51 patients accrued to this study, 1 was not eligible because the child was older than 6 years. Fifty patients were eligible and had either...

journal_title：Neuro-oncology

authors： Mahoney DH Jr,Cohen ME,Friedman HS,Kepner JL,Gemer L,Langston JW,James HE,Duffner PK,Kun LE

更新日期：2000-10-01 00:00:00

abstract：Background:The mesenchymal phenotype in glioblastoma (GBM) and other cancers drives aggressiveness and treatment resistance, leading to therapeutic failure and recurrence of disease. Currently, there is no successful treatment option available against the mesenchymal phenotype. Methods:We classified patient-derived GB...

journal_title：Neuro-oncology

authors： Olmez I,Love S,Xiao A,Manigat L,Randolph P,McKenna BD,Neal BP,Boroda S,Li M,Brenneman B,Abounader R,Floyd D,Lee J,Nakano I,Godlewski J,Bronisz A,Sulman EP,Mayo M,Gioeli D,Weber M,Harris TE,Purow B

更新日期：2018-01-22 00:00:00

abstract：:Ependymomas are rare primary tumors of the central nervous system in children and adults that comprise histologically similar but genetically distinct subgroups. The tumor biology is typically more associated with the site of origin rather than being age-specific. Genetically distinct subgroups have been identified by...

journal_title：Neuro-oncology

authors： Wu J,Armstrong TS,Gilbert MR

更新日期：2016-07-01 00:00:00

abstract：:Angiogenesis plays a key role in glioblastoma biology and antiangiogenic agents are under clinical investigation with promising results. However, the angiogenic profiles of patients with glioblastoma and their clinical significance are not well understood. Here we characterize the serum angiogenic profile of patients ...

journal_title：Neuro-oncology

authors： Crocker M,Ashley S,Giddings I,Petrik V,Hardcastle A,Aherne W,Pearson A,Bell BA,Zacharoulis S,Papadopoulos MC

更新日期：2011-01-01 00:00:00

abstract：Background:Malignant glioma (MG) is a devastating neuro-oncologic disease with almost invariably poor prognosis. Prognostic awareness (PA) is the awareness of incurable disease and shortened life expectancy (LE). Accurate PA is associated with favorable psychological outcomes at the end of life (EoL) for patients with ...

journal_title：Neuro-oncology

authors： Diamond EL,Prigerson HG,Correa DC,Reiner A,Panageas K,Kryza-Lacombe M,Buthorn J,Neil EC,Miller AM,DeAngelis LM,Applebaum AJ

更新日期：2017-10-19 00:00:00

abstract：BACKGROUND:The majority of WHO grades II and III gliomas harbor a missense mutation in the metabolic gene isocitrate dehydrogenase (IDH) and accumulate the metabolite R-2-hydroxyglutarate (R-2HG). Prior studies showed that this metabolite can be detected in vivo using proton magnetic-resonance spectroscopy (MRS), but t...

journal_title：Neuro-oncology

authors： de la Fuente MI,Young RJ,Rubel J,Rosenblum M,Tisnado J,Briggs S,Arevalo-Perez J,Cross JR,Campos C,Straley K,Zhu D,Dong C,Thomas A,Omuro AA,Nolan CP,Pentsova E,Kaley TJ,Oh JH,Noeske R,Maher E,Choi C,Gutin PH,Ho

更新日期：2016-02-01 00:00:00

abstract：:Survival alone is no longer an adequate outcome for persons with brain tumors; the quality of the survivorship experience should be viewed with equal importance. Symptom management is a significant component of quality survivorship care. Regardless of their histology, brain tumors and therapies used to treat them prod...

journal_title：Neuro-oncology

authors： Amidei C

更新日期：2018-11-09 00:00:00

abstract：BACKGROUND:A cDNA library made from 2 glioma cell lines, U87MG and T98G, was screened by serological identification of antigens by recombinant cDNA expression (SEREX) using serum from a glioblastoma patient. Elongation factor Tu GTP binding domain containing protein 1 (EFTUD1), which is required for ribosome biogenesis...

journal_title：Neuro-oncology

authors： Saito K,Iizuka Y,Ohta S,Takahashi S,Nakamura K,Saya H,Yoshida K,Kawakami Y,Toda M

更新日期：2014-12-01 00:00:00

abstract：:The homeobox transcription factor OTX2 plays an essential role during embryonic brain development. It is normally silenced in the adult brain, but is overexpressed by genomic amplification or other mechanisms in the majority of medulloblastomas (MBs). Retinoic acids (RAs) can suppress OTX2 expression and inhibit MB gr...

journal_title：Neuro-oncology

authors： Bai R,Siu IM,Tyler BM,Staedtke V,Gallia GL,Riggins GJ

更新日期：2010-07-01 00:00:00

abstract：:The effects of combining histone deacetylase (HDAC) inhibitors and proteasome inhibitors were evaluated in both established glioblastoma multiforme (GBM) cell lines and short-term cultures derived from the Mayo Clinic xenograft GBM panel. Coexposure of LBH589 and bortezomib at minimally toxic doses of either drug alon...

journal_title：Neuro-oncology

authors： Yu C,Friday BB,Yang L,Atadja P,Wigle D,Sarkaria J,Adjei AA

更新日期：2008-06-01 00:00:00

abstract：:Glioblastoma multiforme, a highly aggressive tumor of the central nervous system, has a dismal prognosis that is due in part to its resistance to radio- and chemotherapy. The protein kinase C (PKC) family of serine threonine kinases has been implicated in the formation and proliferation of glioblastoma multiforme. Mem...

journal_title：Neuro-oncology

authors： Azoitei N,Kleger A,Schoo N,Thal DR,Brunner C,Pusapati GV,Filatova A,Genze F,Möller P,Acker T,Kuefer R,Van Lint J,Baust H,Adler G,Seufferlein T

更新日期：2011-07-01 00:00:00

abstract：BACKGROUND:EORTC study 22033-26033 showed no difference in progression-free survival between high-risk low-grade glioma receiving either radiotherapy (RT) or Temozolomide (TMZ) chemotherapy alone as primary treatment. Considering the potential long-term deleterious impact of radiotherapy on memory functioning, this stu...

journal_title：Neuro-oncology

authors： Klein M,Drijver AJ,van den Bent MJ,Bromberg JC,Hoang-Xuan K,Taphoorn MJB,Reijneveld JC,Ben Hassel M,Vauleon E,Eekers DBP,Tzuk-Shina T,Lucas A,Freixa SV,Golfinopoulos V,Gorlia T,Hottinger AF,Stupp R,Baumert BG

更新日期：2020-11-01 00:00:00

abstract：BACKGROUND:Fatigue is common among glioma patients undergoing radiotherapy (RT) and impacts quality of life (QOL). We evaluated whether armodafinil, a wakefulness-promoting medication, improves fatigue in glioma patients undergoing RT. METHODS:Eligibility criteria included age ≥18 years, Karnofsky performance status ≥...

journal_title：Neuro-oncology

authors： Lee EQ,Muzikansky A,Drappatz J,Kesari S,Wong ET,Fadul CE,Reardon DA,Norden AD,Nayak L,Rinne ML,Alexander BM,Arvold ND,Doherty L,Stefanik J,LaFrankie D,Ruland SF,Pulverenti J,Smith KH,Gaffey SC,Hammond S,Wen PY

更新日期：2016-06-01 00:00:00

abstract：:This paper explicates the impact of tumor capillary permeability for glioma World Health Organization (WHO) grades II to IV on brain-penetrant drug entry and distribution within the tumor and the brain adjacent to tumor (leading edge). In addition, we consider the distribution of non-brain penetrant drugs and how, in ...

journal_title：Neuro-oncology

authors： Levin VA,Ellingson BM

更新日期：2018-04-09 00:00:00

abstract：BACKGROUND:Diagnostic accuracy in previous studies of O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) PET in patients with suspected recurrent glioma may be influenced by prolonged dynamic PET acquisitions, heterogeneous populations, different non-standard-of-care therapies, and PET scans performed at different time point...

journal_title：Neuro-oncology

authors： Bashir A,Mathilde Jacobsen S,Mølby Henriksen O,Broholm H,Urup T,Grunnet K,Andrée Larsen V,Møller S,Skjøth-Rasmussen J,Skovgaard Poulsen H,Law I

更新日期：2019-12-17 00:00:00

abstract：:Angiogenesis is necessary for tumor growth beyond a volume of approximately 2 mm(3). This observation, along with the accessibility of tumor vessels to therapeutic targeting, has resulted in a research focus on inhibitors of angiogenesis. A number of endogenous inhibitors of angiogenesis are found in the body. Some of...

journal_title：Neuro-oncology

authors： Rege TA,Fears CY,Gladson CL

更新日期：2005-04-01 00:00:00

abstract：:The purpose of this study was to determine the dose-limiting toxicities, maximum tolerated dose, pharmacokinetics, and intratumor and brain distribution of motexafin gadolinium (MGd) with involved field radiation therapy in children with newly diagnosed intrinsic pontine gliomas. MGd was administered as a 5-min intrav...

journal_title：Neuro-oncology

authors： Bradley KA,Pollack IF,Reid JM,Adamson PC,Ames MM,Vezina G,Blaney S,Ivy P,Zhou T,Krailo M,Reaman G,Mehta MP,Children's Oncology Group.

更新日期：2008-10-01 00:00:00